Shareholders of JW (Cayman) Therapeutics (HKG:2126) will meet June 3 to vote on a proposed license agreement between the company and substantial shareholder Juno Therapeutics, a Thursday Hong Kong bourse filing said.

Under the agreement entered into in April, the drugmaker granted Juno Therapeutics a non-exclusive license under the JW sLVV Manufacturing Process solely to develop, commercialize, manufacture, or have manufactured certain products worldwide.

The scope of the agreement encompasses any product involving the use of genetically engineered cells to treat any disease or conditions. Juno Therapeutics or affiliates either own the intellectual property rights of these products or have obtained licenses for them.